Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) Equity Average (2016 - 2025)

Historic Equity Average for Macrogenics (MGNX) over the last 13 years, with Q3 2025 value amounting to $56.8 million.

  • Macrogenics' Equity Average fell 3612.78% to $56.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.8 million, marking a year-over-year decrease of 3612.78%. This contributed to the annual value of $134.3 million for FY2024, which is 880.98% down from last year.
  • Per Macrogenics' latest filing, its Equity Average stood at $56.8 million for Q3 2025, which was down 3612.78% from $62.9 million recorded in Q2 2025.
  • Macrogenics' Equity Average's 5-year high stood at $334.8 million during Q2 2021, with a 5-year trough of $56.8 million in Q3 2025.
  • Moreover, its 5-year median value for Equity Average was $132.7 million (2022), whereas its average is $164.3 million.
  • In the last 5 years, Macrogenics' Equity Average skyrocketed by 5346.95% in 2021 and then tumbled by 5651.98% in 2022.
  • Quarter analysis of 5 years shows Macrogenics' Equity Average stood at $265.5 million in 2021, then tumbled by 50.1% to $132.5 million in 2022, then soared by 30.8% to $173.3 million in 2023, then plummeted by 31.87% to $118.1 million in 2024, then plummeted by 51.88% to $56.8 million in 2025.
  • Its last three reported values are $56.8 million in Q3 2025, $62.9 million for Q2 2025, and $97.6 million during Q1 2025.